Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis

INTRODUCTION: Breast Cancer Prevention Trial (BCPT) and Multiple Outcomes of Raloxifene (MORE) data have been interpreted to indicate that tamoxifen reduces the risk of ER+ but not ER- breast carcinogenesis. We explored whether these data also support an alternative hypothesis, that tamoxifen influe...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Esserman, Laura J, Ozanne, Elissa M, Dowsett, Mitch, Slingerland, Joyce M
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2005
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC1410777/
https://ncbi.nlm.nih.gov/pubmed/16457695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr1342
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires